Galapagos NV (Galapagos NV) Debt-to-Revenue

: N/A (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Debt-to-Revenue measures a company's ability to pay off its debt.

Galapagos NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.1 Mil. Galapagos NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.4 Mil. Galapagos NV's annualized Revenue for the quarter that ended in Dec. 2023 was $-912.2 Mil. Galapagos NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was -0.01.

Galapagos NV Debt-to-Revenue Historical Data

The historical data trend for Galapagos NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.03

0.06

0.12

0.09

0.04

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	0.02	0.03	0.03	N/A

Competitive Comparison

For the Biotechnology subindustry, Galapagos NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV Debt-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Galapagos NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Debt-to-Revenue falls into.

Galapagos NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Galapagos NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.073	+	5.391)	/	261.422
	=	0.04

Galapagos NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(5.073	+	5.391)	/	-912.208
	=	-0.01

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Galapagos NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.